BCR-ABL1 Panel Information

HemeScreen® BCR/ABL1 screening reagents are research use only reagents that detect three major BCR/ABL1 isoforms (p190, p210, and p230) and one minor isoform (p203) associated with BCR/ABL1-induced leukemogenesis, including chronic myeloid leukemia (CML) and acute lymphocytic leukemia (ALL). The presence of fusion isoforms can be associated with diagnosis, therapeutic monitoring, detection of minimal residual disease (MRD), therapeutic selection for response to TKIs, and/or stem cell transplantation. The results from HemeScreen BCR/ABL1 are qualitative and DNA sequencing is required to identify specific isoforms.

Technical Overview IFU SDS Shop